Tarceva could be given to patients across all types of lung cancer - Medical News Today

The NICE decision, on having NHS cover Tarceva as a first-line treatment for patients with lung cancer, may be a double-edge sword. Despite high response rates in mutation positive patients, approximately 30-40% of patients with the appropriate biomarker ...

Research and Markets: Tarceva (Pancreatic Cancer) - Analysis and Forecasts to 2020 - Boston Globe

Dublin - Research and Markets (http://www.researchandmarkets.com/research/qw6kmn/tarceva_pancreati) has announced the addition of GlobalData 's new report "Tarceva (Pancreatic Cancer) - Analysis and Forecasts to 2020" to their offering.

Class Of Cancer Drugs Linked To Eye Infections, MHRA Warns - Newsinferno.com

Erbitux (cetuximab), Tarceva (erlotinib), Iressa (gefitinib) and Vectibix, are used to treat EGFR-expressing tumors. The cornea is covered with a layer of epithelium, which may become damaged when patients are receiving EGFR treatment.

Astellas announces favorable judgment in patent infringement case - comcast.net

5,747,498 (reissued as RE 41,065) and 6,900,221, which cover Tarceva (erlotinib) tablets and their use. The lawsuit was based on an Abbreviated New Drug Application (ANDA) filed by Mylan seeking permission from the FDA to manufacture and market a generic ...

22 Biopharma Stocks With Breakout Potential in 2012 - Inside Fidelity

The "MARQUEE" trial compares tivantinib plus Takeda's Tarceva against Tarceva alone in previously treated non-small cell lung cancer patients. The study's primary endpoint is overall survival. Peyronie's is a buildup of scar tissue that causes extreme (and ...

OSI Pharmaceuticals, Inc. - Strategic SWOT Analysis Review - new company profile report - Transworld News

The company's flagship product is Tarceva, a small molecule inhibitor of the epidermal growth factor receptor (EGFR) in the Oncology segment. The company's product pipeline include Erlotinib tablets, OSI-906, OSI-027, OSI-930 for oncology, PSN821 ...

Idera Pharmaceuticals Reports First Quarter 2012 Financial Results - Business Wire

Since that time, Merck KGaA has completed three clinical studies of IMO-2055. Top-line Data Announced from a Phase 1b Trial of IMO-2055 in Combination with Tarceva ® and Avastin ® for the Treatment of Non-Small Cell Lung Cancer (NSCLC) During the first ...

Cancer pill effective, but copay higher - USA Today

"But if a patient needs a new targeted therapy like the lung-cancer drug Tarceva, he may end up paying a substantially higher percentage of the cost than he would have had there been a comparable intravenous drug." There is no oral oncology ...

Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction - msnbc.com

Doxorubicin liposomal (Doxil), Eribulin (Halaven), Erlotinib (Tarceva), Everolimus (Afinitor), Exemestane (Aromasin), Fadrozole (Afema), Fluoxymesterone, Fulvestrant (Faslodex), Ganitumab, Gemcitabine (Gemzar), Goserelin (Zoladex), Herceptin SC ...

Compulsory licensing sets off a wave of price cuts in cancer drugs - Livemint.com

And there was largely no competition due to patent protection. But in 2009, Cipla launched a copy of Roche’s Tarceva (erlotinib), challenging the foreign company’s patent on the drug and pricing its version at Rs46,000 for a month’s therapy.